AXSM (Axsome Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

AXSM (Axsome Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

Mkt Cap$9B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$638M

Net Income (TTM)-$183M

EPS (TTM)-$3.69

Free Cash Flow (TTM)-$94M

Gross Margin92.6%

Op. Margin-26.5%

Net Margin-28.7%

FCF Margin-14.7%

P/S Ratio (TTM)13.4x

P/E Ratio (TTM)—

YoY Rev Growth+65.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$95M	$87M	-$6M
Q2 23	$47M	$42M	-$65M
Q3 23	$58M	$51M	-$62M
Q4 23	$72M	$64M	-$98M
Q1 24	$75M	$69M	-$67M
Q2 24	$87M	$79M	-$78M
Q3 24	$105M	$96M	-$63M
Q4 24	$119M	$108M	-$73M
Q1 25	$121M	$112M	-$57M
Q2 25	$150M	$137M	-$37M
Q3 25	$171M	$159M	-$46M
Q4 25	$196M	$184M	-$29M

Valuation

Quarter	P/S	P/E
Q1 23	59.3x	—
Q2 23	47.0x	—
Q3 23	38.4x	—
Q4 23	31.7x	—
Q1 24	34.2x	—
Q2 24	29.4x	—
Q3 24	25.3x	—
Q4 24	22.2x	—
Q1 25	19.9x	—
Q2 25	17.3x	—
Q3 25	15.3x	—
Q4 25	13.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$6M	-$6M
Q2 23	-$55M	-$55M
Q3 23	-$54M	-$54M
Q4 23	-$30M	-$30M
Q1 24	-$53M	-$54M
Q2 24	-$30M	-$30M
Q3 24	-$19M	-$18M
Q4 24	-$26M	-$26M
Q1 25	-$43M	-$43M
Q2 25	-$32M	-$32M
Q3 25	$1M	$988K
Q4 25	-$19M	-$19M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$71K
Q2 23	$133K
Q3 23	$371K
Q4 23	$7K
Q1 24	$98K
Q2 24	$52K
Q3 24	$150K
Q4 24	$30K
Q1 25	$0
Q2 25	$0
Q3 25	$58K
Q4 25	$351K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+163.7%
Q2 23	+429.5%	+132.8%
Q3 23	+243.1%	+102.4%
Q4 23	+193.5%	+101.5%
Q1 24	-20.7%	+40.9%
Q2 24	+86.7%	+47.8%
Q3 24	+81.3%	+39.6%
Q4 24	+66.0%	+12.7%
Q1 25	+62.0%	+25.4%
Q2 25	+72.1%	+13.0%
Q3 25	+63.2%	+29.7%
Q4 25	+65.0%	+17.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$13M	13.7%
Q2 23	$16M	34.1%
Q3 23	$15M	25.7%
Q4 23	$19M	26.4%
Q1 24	$20M	26.9%
Q2 24	$21M	24.5%
Q3 24	$22M	20.7%
Q4 24	$22M	18.5%
Q1 25	$23M	19.2%
Q2 25	$25M	16.4%
Q3 25	$23M	13.5%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$18M	—	—	$74M
Q2 23	$21M	$52M	$27M	—
Q3 23	$29M	—	—	$83M
Q4 23	$31M	—	—	$87M
Q1 24	$37M	—	—	$99M
Q2 24	$50M	—	—	$104M
Q3 24	$45M	—	—	$96M
Q4 24	$55M	—	—	$113M
Q1 25	$45M	—	—	$121M
Q2 25	$50M	$94M	$36M	—
Q3 25	$40M	$109M	$41M	—
Q4 25	$49M	—	—	$169M

Revenue Segments

Quarter	License	Product	Royalty
Q1 23	$66M	$29M	$272K
Q2 23	—	$46M	$683K
Q4 23	—	$71M	$783K
Q1 24	—	$74M	$903K
Q2 24	—	$87M	$646K
Q3 24	—	$104M	$1M
Q1 25	—	$120M	$1M
Q2 25	—	$149M	$1M
Q3 25	—	$170M	$2M
Q4 25	—	$195M	—

Revenue by Geography

Quarter	Non-US	United States
Q3 23	$1M	$56M
Q1 24	$903K	$73M
Q2 24	$1M	$85M
Q3 24	$1M	$103M
Q4 24	$1M	$117M
Q1 25	$1M	$119M
Q2 25	$3M	$146M
Q3 25	$1M	$169M
Q4 25	$353K	$194M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$247M	$0	$247M
Q2 23	$437M	$0	$437M
Q3 23	$417M	$0	$417M
Q4 23	$386M	$0	$386M
Q1 24	$331M	$0	$331M
Q2 24	$316M	$0	$316M
Q3 24	$327M	$0	$327M
Q4 24	$315M	$0	$315M
Q1 25	$301M	$0	$301M
Q2 25	$303M	$0	$303M
Q3 25	$325M	$0	$325M
Q4 25	$323M	$0	$323M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	44M	+0.2%
Q2 23	44M	+0.3%
Q3 23	47M	+7.9%
Q4 23	47M	+0.5%
Q1 24	47M	+0.1%
Q2 24	48M	+0.4%
Q3 24	48M	+1.2%
Q4 24	49M	+0.8%
Q1 25	49M	+0.7%
Q2 25	49M	+1.2%
Q3 25	50M	+1.2%
Q4 25	51M	+1.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	$0	11
FY 16	$0	22
FY 17	$0	25
FY 18	$0	29
FY 19	$0	45
FY 20	$0	60
FY 21	$0	108
FY 22	$131K	383
FY 23	$497K	545
FY 24	$565K	683
FY 25	$690K	925